Baric Transcribed Interview (Redacted) — page 99

DC.Scheduling@LexitasLegal.com MS. SALAZAR: So when you have a separate technical aim you just have two completely separate experiments that are never going to meet, that have zero connectivity? That, to me, I don't know, but that doesn't make logical sense to me that you would have -- why wouldn't you have separate -- DR. BARIC: I think you're making an incorrect intuitive leap. I was trying to describe the two approaches that were being used to control viruses in a cave setting. The other approach was that having identified strains of viruses that had spike genes that could infect human cells and potentially cause human disease, those spike genes would be isolated and placed in virus vaccine vectors that would then be delivered to the bats in the cave, is the second approach. The first approach is immediate innate immune knockdown so that the virus burden in the cave goes down and it's less likely that a soldier will be infected. The second approach is to immunize the bats in that cave so that a virus burden would be very, very low, and it would be long-term protection so the cave could be used for a much longer period of time. So they are linked but they're different approaches to abrogate virus replication. MS. SALAZAR: Okay. Would this have been subject to the gain-of-function pause in 2017?